Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PRME, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| PG-011 nasal spray 0.6%(twice daily) | Seasonal Allergic Rhinitis | Phase 3 · NCT07146126 | Not yet recruiting |
| PG-011Gel | Atopic Dermatitis | Phase 3 · NCT06587685 | Recruiting |
| Recommended treatment schedule | COVID-19 | Phase 3 · NCT05249790 | Withdrawn |
| Usual care | COVID-19 | Phase 3 · NCT05249790 | Withdrawn |
| PM359 | Chronic Granulomatous Disease | Phase 1/2 · NCT06559176 | Enrolling by invitation |
| PM577a | Wilson Disease | Phase 1/2 · NCT07748403 | Recruiting |
| PM647a | Alpha-1 Antitrypsin Deficiency | Phase 1/2 · NCT07887347 | Not yet recruiting |
| Pumecitinib Nasal Spray 0.3% | Seasonal Allergic Rhinitis | Phase 2 · NCT06837233 | Completed |
| Pumecitinib Nasal Spray 0.6% | Seasonal Allergic Rhinitis | Phase 2 · NCT06837233 | Completed |
| PG-033 | Lichen Simplex Chronicus | Phase 1 · NCT07013097 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PRME holds $61.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $38.9M/quarter from operations, an estimated runway of 4.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 84 · High
Because certain elements of management’s plans to mitigate the conditions that raised substantial doubt about the Company’s ability to continue as a going concern are outside of the Company’s control, including the ability to raise capital through an equity or other financing, those elements cannot be considered…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PRME files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| David R. Liu 10% owner |
Insider | 20,240,945 | 11.16% | 2025-06-30 |
| Robert Nelsen Director, 10% owner · +214,062 options |
Insider | 18,642,036 | 10.28% | 2026-11-12 |
| ARCH Venture Partners XII, LLC 10% owner |
Insider | 18,486,894 | 10.19% | 2025-08-01 |
| ARCH Venture Partners X, LLC 10% owner Includes shares also reported by ARCH Venture Partners XII, LLC, counted once |
Insider | 18,486,894 | 10.19% | 2025-08-01 |
| Arch Venture Management, Llc | Institution (13F) | 18,486,894 | 10.19% | 2026-09-30 |
| Alphabet Inc. | Institution (13F) | 16,562,498 | 9.13% | 2026-09-30 |
| Blackrock Inc. | Institution (13F) | 10,715,813 | 5.91% | 2026-09-30 |
| ARK Investment Management LLC | Institution (13G, 5%+) | 10,043,508 | 5.54% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 6,148,637 | 3.39% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 4,579,587 | 2.52% | 2026-09-30 |
| T. Rowe Price Investment Management, Inc | Institution (13F) | 4,555,789 | 2.51% | 2026-09-30 |
| Balyasny Asset Management LP | Institution (13F) | 3,560,355 | 1.96% | 2026-09-30 |
Share count 181,376,856 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-06-05 filed 2026-06-08 |
Chung Wendy |
Option award (A) | 75,000 | – | – |
| 2026-06-05 filed 2026-06-08 |
Cahill Thomas |
Option award (A) | 75,000 | – | – |
| 2026-06-05 filed 2026-06-08 |
Kelly Michael Aaron |
Option award (A) | 75,000 | – | – |
| 2026-06-05 filed 2026-06-08 |
Marrazzo Jeffrey D |
Option award (A) | 75,000 | – | – |
| 2026-06-05 filed 2026-06-08 |
Schenkein David P |
Option award (A) | 75,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRME and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →